Know How Inpefa Stacks Up to Other SGLT2 Inhibitors
New Inpefa (sotagliflozin) will try to compete with other SGLT2 inhibitors (Farxiga, Jardiance, etc).
Inpefa is NOT approved for managing type 2 diabetes yet...although A1c lowering seems similar to other SGLT2 inhibitors.
Instead, expect reps to tout Inpefa to reduce heart failure risk...especially for patients with a recent HF hospitalization.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: PA includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote